Author

N. N. Sanford

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Oct 2026

Clinical Endpoints in Trials of Metastasis-Directed Therapy in Oligometastatic Cancer: A Systematic Review and Surrogacy Analysis.

BACKGROUND The oligometastatic state is characterized by limited metastatic burden for which metastasis-directed therapy (MDT) may provide durable control. Endpoint selection in MDT trials is poorly standardized and may not reflect long-term benefit or patient priorities. We systematically reviewed clinical endpoints i...

David C. Chen, E. Khosh Kish, Seung-Min Lee et al. · The Oncologist · 0 citations

Sep 2026

Expert consensus on clinical trials for use of systemic therapy in patients with hepatocellular carcinoma undergoing surgical and locoregional therapies.

BACKGROUND Advances in systemic therapy for advanced hepatocellular carcinoma (HCC) have fuelled a growing interest in evaluating these therapies in earlier stages of disease. However, trial design remains challenging due to the marked clinical and biological heterogeneity of early-stage and intermediate-stage HCC. O...

M. Yarchoan, J. Llovet, R. K. Kelley et al. · Gut · 1 citation

Editorial Open access Aug 2026

Patient‐reported outcomes and targeted therapeutic escalation in NRG Oncology/RTOG 1010: When intensification fails to translate to improved outcomes

In NRG Oncology/RTOG 1010, HER2‐targeted escalation did not improve survival or patient‐reported outcomes in localized esophageal adenocarcinoma. The study illustrates that biologic plausibility and metastatic success do not guarantee benefit in the curative‐intent setting and emphasizes the need for rigorous, patient‐...

T. J. Brown, N. Hornstein, U. Grewal et al. · Cancer · 0 citations